March 12, 2026
Curatis and Neupharma sign development agreement for corticorelin in Japan
Switzerland-based Curatis has signed an exclusive licensing and development agreement with Neupharma for corticorelin (C-PTBE-01) to treat peritumoral brain oedema in Japan.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







